Novo Nordisk's Pipeline Bruises Undermine a Quarter of Operational Beating
Published on 08/06/2026 at 20:41 | Redaktion boerse-global.de
For Europe's most valuable pharmaceutical company, the arithmetic of the second quarter of 2026 was flattering while the narrative turned unforgiving. Novo Nordisk delivered an adjusted operating profit of 33.4 billion Danish kroner — comfortably ahead of the 28.74 billion analysts had penciled in — and raised its full-year guidance to a range of 0 to minus 6 percent growth at constant exchange rates, a clear improvement on the previous minus 4 to minus 12 percent projection. Adjusted revenue climbed 7 percent to 78.5 billion kroner. By the numbers, this was a quarter of quiet recovery.
The market, however, refused to play along. Shares in Copenhagen slid as much as 7.1 percent on the day of the release, a reaction the options market had only partially anticipated — Saxo Bank noted that traders had priced in a swing of roughly 8 percent ahead of the August 5 report. The sell-off was driven less by the headline figures than by what lay beneath them: a 6.3 billion kroner non-cash impairment, including 4.0 billion kroner written off against the experimental oral candidate monlunabant, and oral Wegovy sales of 3.22 billion kroner that fell short of the 3.3 billion consensus. Investors who had hoped the pill would reignite growth got a reminder that momentum in this franchise is not guaranteed.
The clinical setbacks compounded the disappointment. In a study involving type-2 diabetes patients, CagriSema — once viewed as the natural successor to semaglutide — failed to match Eli Lilly's tirzepatid on blood-sugar reduction. Days earlier, on July 31, the phase-3 ZEUS trial for the IL-6 antibody ziltivekimab missed its primary endpoint of reducing major adverse cardiovascular events versus placebo. That the company had reported positive ZEUS results in early August for patients with atherosclerotic cardiovascular disease and chronic kidney disease only muddied the picture further, leaving investors to weigh conflicting signals from the same program.
The stock has since staged a partial rebound, gaining 2.54 percent on Thursday to trade at 39.70 euros, though that still leaves it down 11.17 percent over seven trading days and 27.63 percent below its January record high. The whipsawing reflects a deeper tension: management's operational credibility is intact, but its pipeline promises are under mounting scrutiny.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
CEO Mike Doustdar responded on Wednesday with a pledge to accelerate research and pursue targeted smaller acquisitions to replenish the portfolio — a strategic necessity given that semaglutide patents begin expiring in the early 2030s. The urgency is understandable. A blockbuster molecule nearing patent cliffs needs a successor, and the current generation of candidates has stumbled at precisely the wrong moment.
Analysts are recalibrating. Morningstar's Karen Andersen cut her fair value estimate from 311 to 285 Danish kroner (equivalent to a reduction from $48 to $44), citing intensifying price pressure from oral cash-pay competitors and the CagriSema clinical setback. Jefferies' Michael Leuchten struck a similar chord, saying the quarterly results and soft Wegovy pill sales relative to expectations leave "many questions open" about the company's competitiveness heading into 2027.
One bright spot came from the courtroom rather than the lab. A district court in The Hague issued a preliminary injunction against Dutch pharmacy Ceban Ziekenhuisfarmacie, barring it from distributing Semanova, a compounded nasal spray version of semaglutide that infringed Novo Nordisk's supplementary protection certificate SPC 300936, valid until 2031. The ruling underscores how the company is fighting on multiple fronts — against Eli Lilly in the clinic, against compounders in the courts — to defend a market it effectively created.
Novo Nordisk at a turning point? This analysis reveals what investors need to know now.
Meanwhile, the buyback machine grinds on. Between February 4 and August 3, Novo Nordisk repurchased roughly 27.1 million B-shares worth 7.53 billion kroner under a 12-month program sized at 15 billion kroner. The European Commission's July approval of the Wegovy pill as the EU's first oral GLP-1 treatment for weight management, alongside a 7.2-mg pre-filled pen, offers another reason for measured optimism.
Two dates now loom large: the capital markets day on September 21 and the nine-month results on November 4. Between now and then, the central question is whether Novo Nordisk can convince investors that its innovation engine still runs at full throttle — or whether the era of effortless dominance in obesity care is quietly drawing to a close.
Ad
Novo Nordisk Stock: New Analysis - 6 August
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
